About
Small molecule cancer drugs that modulate protein degradation pathways
Areas of Focus
Categories
Small Molecule Pharmaceutical
Team (18)
Ali Behbahani
M.D.
Monte Rosa Therapeutics
team_member
Andrew Funderburk
SVP, Head of IR and Strategic Finance
Monte Rosa Therapeutics
team_member
Andrew Schiff
M.D.
Monte Rosa Therapeutics
team_member
Chandra P. Leo
M.D.
Monte Rosa Therapeutics
team_member
Christine Siu
M.B.A.
Monte Rosa Therapeutics
team_member
Eric A. Hughes
M.D., Ph.D.
Monte Rosa Therapeutics
team_member
Clinical Trials (3)
View allTotal Trials
3
As Lead Sponsor
3
As Collaborator
0
Total Enrollment
382
By Phase
PHASE1: 2PHASE1/PHASE2: 1
By Status
RECRUITING: 2COMPLETED: 1
Clinical Trials Pipeline3 trials
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Phase 1/2
Phase 2/3
N/A
2021
2022
2023
2024
2025
2026
2027
2028
Today
Hover over trial bars to see details
Recent Trials
NCT07119125Lead Sponsor
A First-in-human, 3-part Study of MRT-8102 in Healthy Participants and Participants at Cardiovascular Risk With Elevated CRP
PHASE1Recruiting
100 participants
Started: Jun 27, 2025 · Completed: Mar 31, 2026
NCT06597799Lead Sponsor
First-in-human Study of MRT-6160 in Healthy Subjects
PHASE1Completed
108 participants
Started: Aug 7, 2024 · Completed: Apr 10, 2025
NCT05546268Lead Sponsor
Study of Oral MRT-2359 in Selected Cancer Patients
PHASE1/PHASE2Recruiting
174 participants
Started: Oct 12, 2022 · Completed: Nov 30, 2027
Locations (1)
Headquarters
Basel, Switzerland
Map
Loading map...